Loading stock data…
Rhythm Pharmaceuticals, Inc. (RYTM)
$102.10-0.56 (-0.55%)
Market ClosedLast close Jul 24
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rhythm Pharmaceuticals, Inc. in the Healthcare sector is trading at $102.10 with a market capitalization of $5.8B. Wall Street consensus targets $138.36 (14 analysts), implying a +35.5% move over the next 12 months. The stock is currently 16% below its 52-week high of $122.20, remaining 3.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +35.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $60.11M↑ | $57.25M↑ | $51.30M↑ | $48.50M↑ | $32.70M |
| Gross Profit | $52.95M↑ | $52.45M↑ | $45.80M↑ | $42.96M↑ | $29.06M |
| Operating Income | -$52.36M↓ | -$47.06M↑ | -$52.65M↓ | -$45.30M↑ | -$47.00M |
| Net Income | -$55.64M↓ | -$47.51M↑ | -$52.90M↓ | -$46.63M↑ | -$49.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.81B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-85.30%
Volume
Today's trading volume
437,264
Recent News
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the best biotech stocks on this list. TheFly reported on June 16 that Canaccord analyst Whitney Ijem increased the price target on RYTM to $151 from $143 while maintaining a Buy rating. The update […]
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Intel Stock and 3 Other Winners I Found Using Barchart’s High-Octane Stock Screener
One feature within the Barchart Stock Screener tool that resonated with me is a pre-built filter known as the J-Pattern or J-Curve.
Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder?
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the most promising healthcare stocks according to Wall Street analysts. On June 13, Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) shared preliminary results from its ongoing Phase 2 trial of setmelanotide for Prader-Willi syndrome (PWS) at the Endocrine Society’s Annual Meeting in Chicago. The company said the data showed meaningful improvements […]
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
Rhythm Pharmaceuticals, Inc. (NASDAQ: RGPX) reported that setmelanotide therapy produced robust, sustained and clinically significant weight loss in patients with acquired hypothalamic obesity at 2.5 years. Alongside the long-term setmelanotide results, Rhythm reported that bivamelagon...